Hyperuricemia on Hypertension and Metabolic Syndrome

National Institute of Cardiology Ignacio Chavez

Status and phase: Completed; Phase 2

Conditions: Metabolic Syndrome Parameters; Hepatic Enzymes; Uric Acid Levels; Systolic and Diastolic Blood Pressure Levels

Treatments: Other: placebo; Drug: Allopurinol

Study type: Interventional

Funder types: Other

Identifiers

NCT01157936

ALOPURINOL (Other Identifier)

HYPERURICEMIA 2010

Details and patient eligibility

About

The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

Full description

Elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose intake since the last 20 years. Important data supporting this fact can be reflected on incidence and prevalence of Metabolic syndrome and hyperuricemia.

A peculiar effect of fructose intake demonstrated in animal models is the development of elevated uric acid levels; also some studies have found a clear association between hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney disease and metabolic syndrome.

Taking into account the existing evidence, our clinical research team presents this protocol as a way to evaluate the effect of uric acid treatment and its relation with Fructose consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension.

Confirming evidence with clinical basis may be the initial strategy to create primary prevention programs to control this health problems affecting Mexican Population.

Enrollment: 40 estimated patients

Sex: All

Ages: 25 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• adults with blood pressure from 120/80 mmHg and less than 140/90 mmHg
• no pharmacological treatment for blood pressure control

Exclusion criteria

• hypertension (more than 140/90mmHg)
• Diabetes Mellitus type 1 or 2
• Chronic kidney disease (MDRD less than 60)
• Hepatic Disease
• Malignancy
• Pregnancy
• patient receiving any medication

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

Allopurinol treatment

Active Comparator group

Treatment:

Drug: Allopurinol

Placebo

Placebo Comparator group

Treatment:

Other: placebo